Schaal, Justin B.
Eriguchi, Yoshihiro
Tran, Dat Q.
Tran, Patti A.
Hawes, Chase
Cabebe, Anthony E.
Pike, Kaitlyn
Trinh, Katie
Ouellette, André J.
Selsted, Michael E.
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (AI22931, AI125141)
National Institute of Dental and Craniofacial Research (DE021341)
National Cancer Institute (P30 CA014089)
Southern California Clinical and Translational Science Institute (TR000130)
Article History
Received: 22 September 2021
Accepted: 18 November 2021
First Online: 6 December 2021
Competing interests
: MES is co-founder and Chief Scientific Officer of Oryn Therapeutics, LLC (Oryn). He is an equity holder but receives no income from Oryn. DQT is scientific director of Oryn and is an equity holder. AJO is an equity holder in Oryn but receives no income. Oryn has licensed technology described in this publication from the University of Southern California and the relationship between Oryn and USC is disclosed to and approved by all parties. All other authors declare no competing interests.